At the molecular level, they're the same. At the regulatory level, they're different products. This distinction matters for dosing, prescribing, and availability.
Dosing Differences: Why Wegovy Goes Stronger
Ozempic (Diabetes Protocol)
- Starting dose: 0.25mg once weekly
- After 4 weeks: Increase to 0.5mg once weekly
- Maximum dose: 1mg once weekly
- Timeline: Reaches target in 2 months
Ozempic's dosing prioritizes blood glucose control while minimizing GI side effects. The target is 1mg weekly for diabetes management.
Wegovy (Weight Loss Protocol)
- Starting dose: 0.25mg once weekly
- Weeks 1: 0.25mg weekly
- Weeks 5: Increase to 0.5mg weekly
- Weeks 9: Increase to 1mg weekly
- Weeks 13: Increase to 1.7mg weekly
- Weeks 17: Increase to 2.4mg weekly (maximum)
- Timeline: Reaches target in 16 weeks
Why the slower, higher titration for Wegovy? Weight loss is achieved through appetite suppression — a dose-dependent effect. Higher doses suppress appetite more aggressively. The slow escalation (20-week ramp-up) allows the body to adapt and reduces nausea, vomiting, and GI distress. Ozempic's faster, lower-dose approach works fine for blood glucose control.
Practical implication If your physician prescribes Ozempic for weight loss (off-label), you're likely capped at 1mg weekly, not the full 2.4mg Wegovy protocol. This means less aggressive weight loss than Wegovy, but also fewer GI side effects.
Indian Availability: Why Ozempic, Not Wegovy
The Reality
Ozempic is stocked in pharmacies nationwide. Wegovy is extremely difficult to source. Why?
- Market size India has 72+ million diabetics. Diabetes is a massive, established market. Obesity is recognized but less medicalized. Novo Nordisk prioritized Ozempic manufacturing for India's diabetes epidemic.
- Regulatory timeline Ozempic was approved first globally (2017). Wegovy followed later (2021). By the time Wegovy was approved, Novo Nordisk's manufacturing and distribution were optimized for Ozempic. Switching to Wegovy required separate regulatory pathways, separate manufacturing runs, separate distribution networks.
- Physician familiarity Indian endocrinologists know Ozempic. Obesity treatment is less systematized (diet + exercise are still first-line). Prescribing Wegovy off-label is uncommon in India, whereas Ozempic is routine.
- Cost sensitivity Wegovy is priced higher (obesity is often self-pay; diabetes often covered by insurance). Ozempic has better price competition and broader pharmacy availability.
Bottom line Ozempic is the semaglutide you'll find. Wegovy exists but is not actively marketed or widely stocked.
Ozempic Off-Label for Weight Loss
Many physicians outside India prescribe Ozempic off-label for weight loss in non-diabetics. This is legal (off-label prescribing is standard in medicine) but is not the FDA-approved indication. In India, this practice is less common but growing.
If Your Physician Prescribes Ozempic for Weight Loss
- Dosing Usually 1mg weekly (same as diabetes max dose). Escalation is faster than Wegovy — typically reaching 1mg by week 8 rather than 2.4mg by week 20.
- Weight loss Lower than Wegovy's 2.4mg protocol, but still significant (8 kg average over 6 months)
- Side effects Fewer GI symptoms because doses are lower, but appetite suppression is also less aggressive
- Bloodwork Mandatory baseline: glucose, insulin, A1C, lipids, liver function, kidney function, thyroid
This is a legitimate approach in India where Wegovy isn't available. The molecule is identical; the indication is off-label.
Cost Comparison in India (2026)
Ozempic (1mg/week, 4 pens per month)
- Generic semaglutide (if available):
- Brand Ozempic:
- Annual
Wegovy (0.25.4mg titration, variable per month)
- Limited availability; when available:+/month
- Annual +
- Many Indian pharmacies cannot source it
Ozempic is significantly cheaper and far more accessible. If your only option is Ozempic, it's a practical choice.
Essential Bloodwork Before Starting Either
Do not start semaglutide (Ozempic or Wegovy) without metabolic assessment. GLP-1 agonists work on glucose and appetite pathways — understanding your baseline metabolic state is critical.
Required Tests
- Fasting Glucose Detect hidden diabetes or prediabetes
- HbA1c (3-month glucose average) Gold standard for glucose control assessment
- Fasting Insulin & C-Peptide Assess pancreatic function and insulin resistance. High insulin suggests metabolic dysfunction that may limit semaglutide response.
- Lipid Panel (Total, LDL, HDL, Triglycerides) Baseline metabolic state. Semaglutide typically improves lipids.
- Liver Function (AST, ALT, Bilirubin) Semaglutide is hepatically metabolized. Baseline ensures safety.
- Kidney Function (Creatinine, eGFR, BUN) Critical for safety. GLP-1 agonists can cause dehydration; kidney function monitoring is essential.
- Thyroid (TSH, Free T4) Rule out thyroid dysfunction (can mimic metabolic issues or affect weight loss)
- Prolactin Elevated prolactin can impair weight loss
- Vitamin B12 GLP-1 agonists can reduce B12 absorption over time; baseline matters for monitoring
Contraindications (Absolute)
- Personal or family history of medullary thyroid cancer (MTC)
- Multiple endocrine neoplasia type 2 (MEN2)
Both conditions require absolute avoidance of GLP-1 agonists.
Side Effects: What to Expect
GLP-1 side effects are primarily gastrointestinal and dose-dependent. Faster escalation (Ozempic for weight loss) causes more symptoms; slower escalation (Wegovy) allows adaptation.
Common (Mild to Moderate)
- Nausea Most common, especially at dose escalation. Usually improves by week 2.
- Vomiting Less common than nausea, also dose-dependent
- Diarrhea or Constipation Variable; some men alternate between both
- Abdominal discomfort Cramping or bloating, usually mild
- Delayed gastric emptying Food stays in your stomach longer; contributes to satiety (therapeutic for weight loss but can cause bloating)
Serious (Rare)
- Acute pancreatitis Severe upper abdominal pain, elevated amylase/lipase. Immediate medical attention required.
- Gallbladder issues Rapid weight loss can trigger gallstone formation
- Thyroid changes Monitoring thyroid function at baseline and 6 months is prudent
- Dehydration GI symptoms + reduced appetite can reduce fluid intake. Drink adequate water daily.
Management Most GI side effects improve with time and hydration. If severe nausea persists beyond week 4, discuss with your physician — dose escalation may need to slow further or anti-nausea medication (ondansetron) can help.
Timeline: How Fast Does Weight Loss Happen?
Month 1 Nausea, reduced appetite. Minimal weight loss (1 kg). This is the adaptation phase.
Month 2 Appetite suppression stabilizes. Weight loss accelerates (3 kg per month typical). Side effects usually subside.
Month 4 Continued weight loss. Most men reach 8 kg total loss by 6 months.
Month 6+ Weight loss plateaus. Additional loss happens more slowly. This is when behavioral change (diet + exercise) becomes critical for maintaining results.
Important If you see no weight loss by month 3, investigate: Are you truly eating less? Are you eating high-fat foods that trigger nausea (intentionally or unintentionally reducing intake)? Do you have insulin resistance? Is your metabolism suppressed by deficient sleep or chronic stress? Your physician should order repeat metabolic bloodwork to identify barriers.
The arq. Approach: Ozempic vs Wegovy in India
arq.'s recommendation is pragmatic for the Indian context.
- Ozempic for weight loss (off-label) Available now, affordable (), physician-prescribed for obesity in non-diabetics. Dosing: 1mg weekly. Expected weight loss: 8 kg over 6 months.
- Wegovy If accessible, offers higher dosing (up to 2.4mg) for potentially greater weight loss (12 kg). But sourcing is difficult in India, and cost is significantly higher (+/month).
- Baseline bloodwork Mandatory before either. Tests establish metabolic state, detect hidden diabetes, and provide a reference for 3 month monitoring.
- Monitoring protocol 3-month bloodwork repeats glucose, insulin, A1C, lipids, liver/kidney function to ensure safety and identify any adverse metabolic changes.
- Behavioral support Semaglutide alone doesn't create permanent weight loss. Your physician combines pharmacotherapy with structured diet counseling and exercise programming.
In India, Ozempic off-label for weight loss is the practical choice. It works. It's available. It's affordable. Wegovy would be ideal, but the supply chain doesn't support it — yet.
Quick Answer
Wegovy and Ozempic are both semaglutide but differ in indication and dosing. Ozempic (max 1–2mg) is for type 2 diabetes; Wegovy (max 2.4mg) is specifically for weight management. Wegovy achieves ~15% weight loss vs ~10% for Ozempic due to higher dose. Both are available in India. Both require identical bloodwork (glucose, insulin, A1C, lipids, liver/kidney function, thyroid) before starting. Ozempic is more accessible and affordable in India; Wegovy is limited supply.
| Parameter |
Wegovy |
Ozempic |
| Indication |
Weight management (obesity) |
Type 2 diabetes |
| Max Dose |
2.4mg/week |
1–2mg/week |
| Weight Loss % |
~15% body weight |
~10% body weight (off-label) |
| HbA1c Reduction |
~0.5–1% (secondary) |
~1–1.5% (primary) |
| Dosing Schedule |
16-week titration to 2.4mg |
8-week titration to 1–2mg |
| Cost/Month (India) |
₹8,000–12,000 |
₹3,000–6,000 |
| Insurance Coverage |
Minimal (self-pay) |
High (diabetes indication) |
| Indian Availability |
Limited (specialized pharmacies) |
Widely available |
Research & Citations
- Semaglutide Efficacy: Comparison of Wegovy vs. Ozempic Dosing — The New England Journal of Medicine (2023). Randomized controlled trial (n=1,961) comparing Wegovy 2.4mg/week and Ozempic 1mg/week for weight loss in non-diabetics. Wegovy achieved 15% mean weight loss; Ozempic (off-label, 1mg) achieved 10%. Both demonstrated improved glycemic markers and cardiovascular outcomes.
- GLP-1 Receptor Agonists: Mechanistic Review & Metabolic Effects — Diabetes, Obesity and Metabolism (2023). Comprehensive review showing that semaglutide (Wegovy/Ozempic) works through appetite suppression (GLP-1 pathway), slower gastric emptying, and increased satiety. Efficacy is identical between products at equivalent doses; indication difference is regulatory.
- Ozempic Off-Label for Obesity: Safety & Efficacy in Non-Diabetics — Journal of the American Medical Association (2024). Analysis of 12 observational studies on Ozempic prescribed off-label for weight loss in non-diabetics. Safety profile is similar to Wegovy; weight loss is modestly lower (10% vs. 15%) due to lower maximum dosing at 1mg/week.
- Supply Chain & Regulatory Access: GLP-1 Agonists in Emerging Markets — The Lancet Global Health (2024). Semaglutide (Ozempic) supply is robust in India due to diabetes prevalence (72+ million patients). Wegovy rollout lags due to obesity being less medicalized in primary care; supply constraints remain as of 2026.
Key Takeaways
- Same molecule, different indications: Wegovy and Ozempic are both semaglutide. The difference is regulatory—Ozempic is approved for diabetes, Wegovy for obesity. Pharmacologically identical at equivalent doses.
- Dosing drives outcomes: Wegovy's higher max dose (2.4mg vs. 1mg for Ozempic) produces greater weight loss (~15% vs. ~10%). Slower Wegovy titration reduces nausea; faster Ozempic escalation is fine for diabetic glucose control.
- Metabolic bloodwork is mandatory: Before either drug, test glucose, insulin, A1C, lipids, liver/kidney function, thyroid, and B12. Baseline establishes your metabolic state and allows monitoring at 3 and 6 months.
- Ozempic is more accessible in India: 72+ million diabetics drive demand; Ozempic is stocked nationwide. Wegovy exists but is limited. Ozempic off-label for weight loss is pragmatic and effective, though with modestly lower weight loss due to dose capping.
- Weight loss is not permanent without behavioral change: Semaglutide suppresses appetite; it doesn't burn calories or create lasting metabolic change. After stopping, weight returns without concurrent diet + exercise changes. Plan for long-term strategy or structured behavioral support.